MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/sh

MAIA Biotechnology, Inc.

Closed underwritten public offering of 20M shares at $1.50/sh, gross proceeds $30M.
Underwriters granted 30-day option to buy up to 3M additional shares for over-allotments.
Net proceeds to fund clinical trials and working capital; offering closed March 4, 2026.
Konik Capital Partners acted as sole book-running manager; 60-day lock-up for insiders.
Offering structured as common stock only with no warrant coverage; led by healthcare investors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MAIA Biotechnology, Inc. entered into Underwriting Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at approximately $30.0 million (effective 2026-03-02).

Action: entry
Agreement: underwriting
Counterparty: Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC
Value: approximately $30.0 million
Effective: 2026-03-02

Exact text from the filing

On March 2, 2026, MAIA Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 20,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-008897

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.